Multiple Myeloma Clinical Trial

MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Summary

The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus.

The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.

This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
Access to a computer or electronic device with internet access, or phone
Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
Willing to give electronically-signed consent
Ability to read questions in English

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

1500

Study ID:

NCT04727294

Recruitment Status:

Recruiting

Sponsor:

HealthTree Foundation

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

HealthTree.org (Online)
Lehi Utah, 84043, United States More Info
Nathan Sweeney, PhD
Contact
800-709-1113
[email protected]
Ana Sahagun, MS
Contact
1-800-709-1113

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

1500

Study ID:

NCT04727294

Recruitment Status:

Recruiting

Sponsor:


HealthTree Foundation

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.